Dr. Daniel S. Pratt, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 255
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Johns Hopkins University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MA license 74297
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- North Shore Medical Center - Salem, MA
- Wentworth-Douglass Hospital Dover, NH
- Cooley Dickinson Hospital Inc,the Northampton, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 255
- Services billed
- 591
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 213 | 177 |
| Established patient office or other outpatient visit, 40-54 minutes | 99 | 81 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 57 | 24 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | 20 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ursodiol Other prescribers in Boston, MA | 392 |
| Mycophenolate Mofetil Other prescribers in Boston, MA | 103 |
| Azathioprine Other prescribers in Boston, MA | 66 |
| Fenofibrate (fenofibrate nanocrystallized) Other prescribers in Boston, MA | 55 |
| Tacrolimus Other prescribers in Boston, MA | 54 |
| Ocaliva (obeticholic acid) | 48 |
| Colchicine Other prescribers in Boston, MA | 43 |
| Omeprazole Other prescribers in Boston, MA | 38 |
| Xifaxan (rifaximin) Other prescribers in Boston, MA | 27 |
| Prednisone Other prescribers in Boston, MA | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 8 payments worth $24,328 in total to this clinician.
| Ipsen Biopharmaceuticals, Inc | $24,175 |
|---|---|
| Perspectum Diagnostics LTD | $133 |
| Gilead Sciences, Inc. | $19.99 |
| Compensation for services other than consulting (speaking, faculty) | $14,043 |
|---|---|
| Consulting Fee | $10,092 |
| Food and Beverage | $173 |
| Education | $19.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc May 14, 2025 | Consulting Fee IQIRVO · Rare Disease | $7,569 |
| Ipsen Biopharmaceuticals, Inc Nov 28, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,760 |
| Ipsen Biopharmaceuticals, Inc Nov 9, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,760 |
| Ipsen Biopharmaceuticals, Inc Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $2,523 |
| Ipsen Biopharmaceuticals, Inc Sep 12, 2025 | Consulting Fee IQIRVO · Rare Disease | $2,523 |
| Gilead Sciences, Inc. Mar 20, 2025 | Education in-kind Company’s description;4297688;GTF;10003648 | $19.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $78,880 in research payments for these studies, mostly to the institutions running them.
- A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)…
Gilead Sciences, Inc. - An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
Gilead Sciences, Inc. - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Ipsen Bioscience Inc. · Active, not recruiting · NCT04526665 - An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Gilead Sciences, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.